Published Date: 01 May 2025
Australia's recent move to lower the starting age for bowel (colorectal) cancer screening from 50 down to 45 years old will mean better outcomes—but it will also increase the burden on an already struggling health care ...
Read Full NewsFindings from a phase 2 trial highlighted lacosamide's effectiveness and safety in treating neonatal seizures, showing significant seizure reduction and tolerability in patients.
Here's some of what is coming soon to NeurologyLive® this week.
Ovid Therapeutics' OV329 shows promise as a safe, effective GABA-AT inhibitor for treating drug-resistant seizures, with strong phase 1 trial results.
FDA-approved RBL shows 95% success and sustained microbiome restoration in recurrent C. difficile.
5 Pulmonology Headlines You Missed in November 2025
Adjunctive Lumateperone Significantly Improves MDD Symptoms by Day 43
Stage 5 CKD May Reverse Female Survival Advantage
1.
Results for Prostate Cancer Are Associated With PSA Nadir 6 Months After Primary RT.
2.
Earlier Info on Financial Stress; Obesity and Second Cancers; Carcinogenic Condoms?
3.
Patients with metastatic breast cancer can predict their response to HER2-targeted therapy using whole-body PET/CT.
4.
The pandemic had little impact on mental health symptoms.
5.
Vaccine elicits strong immune response in patients with pancreatic and colorectal cancer
1.
The Expanding Horizon of PSMA: A Comparative Clinical Review of Theranostics in Prostate Cancer and Beyond
2.
AI-Powered Case Studies in Oncology: Elevating Clinical Influence Through Real-World Data
3.
Understanding the Rare Disease: Werner Syndrome Explained
4.
From Bench to Bedside: The New Era of Lymphoma Treatment and Education
5.
Oncolytic Viruses in Breast Cancer: Unlocking Synergy with Novel Combination Therapies
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
4.
L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients
5.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation